Quentin Hiver

Quentin Hiver

Auto-generated profile, based on publicly available information

Quentin Hiver

Ctr Hosp Valenciennes, Serv Pharm, 114 Ave Desandrouin, F-59300 Valenciennes, France

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2022 in JCO Oncology Practice
Verified
Journal Article
Closed access
QHQuentin Hiver
Quentin Hiver
HHHéloïse HENRY
Héloïse HENRY
MVMichèle Vasseur
Michèle Vasseur
ECElodie Cuvelier
Elodie Cuvelier
ÉRÉmilie Le Rhun
Émilie Le Rhun
NSNicolas SIMON
Nicolas SIMON
PURPOSE: Injectable cytotoxics may be formulated with ethanol. This study sought to quantify the amount of ethanol exposure during chemotherapy infusions. MATERIALS AND METHODS: We first reviewed the antineoplastic drugs (Anatomical Therapeutic and Chemical code L01) and oncologic supportive care drugs (eg, antiemetics) currently available in France, to identify preparations containing ethanol. The amount of ethanol in the final chemotherapy preparation was calculated. Next, we performed a 2-year, single-center, retrospective analysis of injectable antineoplastic drug compounding in routine clinical practice in a French university medical center. Finally, we reviewed our results with regard to the literature data. RESULTS: Ten of the 60 cytotoxic products on the market contained ethanol at concentrations of up to 790 mg/mL, depending on the drug, formulation, and supplier. Several final preparations contained more than 3 g of ethanol per infusion (the maximum recommended by the European Medicines Agency); this was notably the case for gemcitabine, paclitaxel (up to 20 g ethanol per injection, for both), and etoposide (up to 50 g ethanol per infusion). The analysis of our compounding activity showed that 3,172 (4.99%) of the 63,613 chemotherapy preparations (notably paclitaxel) contained more than 3 g of ethanol. None of the oncologic supportive care drugs contained ethanol. CONCLUSION: Patients are exposed to ethanol during the infusion of antineoplastic drugs. With a view to better patient care, physicians and pharmacists should carefully evaluate the risk of ethanol exposure throughout the course of cytotoxic drug treatment.

18 January 2024 in Annales Pharmaceutiques Françaises
Verified
Journal Article
Closed access
MVMarie Vanhaecke
Marie Vanhaecke
MHMarion Hennion-Coussemacq
Marion Hennion-Coussemacq
BDBenjamin Dervaux
Benjamin Dervaux
PAPaul Accaoui
Paul Accaoui
APAmélie Pruvost
Amélie Pruvost
QHQuentin Hiver
Quentin Hiver